MANIPALHOS Q1 2027 Earnings Report

Page 1

MHE-Public Date: August 20, 2026 To, National Stock Exchange of India Limited, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: MANIPALHOS BSE Limited, 20th Floor, P.J. Towers, Dalal Street, Mumbai - 400001. BSE Scrip Code: 544847 Subject: Outcome of the Board meeting of Manipal Health Enterprises Limited (“the Company”) Ref.: Disclosure under Reg. 33 and Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Dear Sir/Ma’am, We would like to inform you that the Board of Directors at its meeting held today i.e., August 20, 2026, which commenced at 6:00 P .M. (IST) and concluded at 6:15 PM (IST) have inter alia considered, and approved the following, subject to applicable provisions of the Companies Act, 2013 and Listing Regulations, including amendments, if any: 1. Unaudited financial results (both standalone and consolidated) of the Company for the quarter ended June 30, 2026, along with Limited Review Report with unmodified opinion issued by the Statutory Auditors of Company. Copies of the same are enclosed herewith; 2. Appointment of M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountants (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company to hold the office for a term of 5 (five) consecutive years from the conclusion of the 16th Annual General Meeting (“AGM”) of the Company to be held in the year 2026 till the conclusion of the 21st AGM to be held in the year 2031, subject to approval of the members of the Company and other statutory requirements; 3. Re-appointment of Dr. Hebri Sudarshan Ballal (DIN: 01195055), as Director, who is liable to retire by rotation, offers himself for re-appointment, at the 16th Annual General Meeting, subject to approval of members of the Company; 4. Re-appointment of Mr. Puneet Bhatia (DIN: 00143973), as Director, who is liable to retire by rotation, offers himself re-appointment, at the 16th Annual General Meeting, subject to approval of members of the Company; 5. Amendment to the Articles of Association (“AOA”) of the Company by inserting a new Article 99.10 relating to the right to nominate directors of the Company, along with the addition of the relevant definitions under Article 4 of the AOA, subject to the approval of the members of the Company. 6. Convening the 16 th Annual General Meeting (“AGM”) of the Company on Tuesday, September 29, 2026 at 11:00 a.m. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OA VM). Further details pertaining to the AGM will be informed in due course of time.

Page 2

Sign in to continue

Your watchlist and earnings event details are available after you sign in.

Page 13

MHE-Public Annexure I Sr. No. Particulars Details M/s. Price Waterhouse Chartered Accountants LLP Dr. Hebri Sudarshan Ballal Mr. Puneet Bhatia 1. Reason for Change viz. appointment, Resignation, removal, death or otherwise. Appointment of M/s. Price Waterhouse Chartered Accountants LLP (ICAI Firm Registration No. 012754N/N500016) as Statutory Auditors of the Company for a period of 5 years starting from the conclusion of 16th AGM till the conclusion of 21 st AGM (i.e. from FY 2026-27 till 2030-31), subject to approval of the Members of the Company and other statutory requirements (including auditor independence requirement for the Company), consequent to completion of tenure of M/s. BSR & Co. LLP, existing statutory auditors of the Company. Re-appointment of Dr. Hebri Sudarshan Ballal as the Non-Executive Director designated as Non - Executive Chairman of the Company, who is liable to retire by rotation, and offers himself for re -appointment subject to the approval of the shareholders, at the 16th Annual General Meeting. Re-appointment of Mr. Puneet Bhatia as the Non-Executive Director of the Company, who is liable to retire by rotation, and offers himself for re - appointment subject to the approval of the shareholders, at the 16th Annual General Meeting. 2. Date of appointment/cessation (as applicable) & term of appointment Based on the recommendation of the Audit Committee, the Board approved and recommended the appointment of M/s Price Waterhouse Chartered Accountants LLP (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company for a term of 5 c onsecutive years, starting from the conclusion of the 16th AGM till the conclusion of the 21st AGM(i.e. from FY 2026-27 till 2030-31), subject to approval of the At the ensuing 16 th Annual General Meeting to be held in FY 2026-27 and his term is liable to retire by rotation. At the ensuing 16 th Annual General Meeting to be held in FY 2026 -27 and his term is liable to retire by rotation.

Page 14

MHE-Public Members and other applicable statutory requirements. 3. Brief profile (in case of appointment) Price Waterhouse & Co Chartered Accountants LLP, having a Firm Registration No. 012754N/N500016, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India. The firm was established in the year 1991 and was converted into a limited liability partnership in the year 2014. The registered office of the firm is at Plot No. 56 & 57, Block DN, Sector V, Salt Lake, Kolkata - 700 091 and more than 15 branch offices in various cities in India as on date. The firm is primarily engaged in providing assurance and auditing services to its clients and is a member firm of Price Waterhouse & Affiliates, a network of firms registered with the Institute of Chartered Accountants of India having Network Registration No. NRN/E/14. Price Waterhouse & Affiliates is a network of separate, distinct and independent Indian Chartered Accountant firms, each of which is registered with the Institute of Chartered Accountants of India. Dr. Hebri Sudarshan Ballal is the Chairman and Non - Executive Director of our Company since October 29, 2010. He holds a bachelor of medicine, bachelor of surgery (MBBS) degree and a degree in doctor of medicine (MD) from the University of Mysore. He has been certif ied by the American Board of Internal Medicine in critical care medicine, nephrology and internal 298 medicine. He was also awarded an honorary fellowship by the Royal College of Physicians, London. He served as a fellow and professor of medicine with the St. Louis University School of Medicine, USA and also the adjunct visiting professor, department of nephrology at Kasturba Medical College, Manipal. He is also the consultant at the nephrology department of Manipal Hospital, Old Airport Road, Bengaluru. He was awarded the Rajyothsava Award, Aryabhata International Mr. Puneet Bhatia is a Non-Executive Director of our Company since February 26, 2015. He holds a bachelor’s degree in commerce from Sriram College of Commerce, University of Delhi and a post graduate diploma in management from the Indian Institute of Management, Calcutta. He is currently the managing director and country head of TPG Capital India Private Limited and has been associated with TPG Capital since 2002. Prior to this, he was Chief Executive, Private Equity Group for GE Capital India. He was also previously associated with Industrial Credit and Investment Corporation of India Limited (ICICI) starting 1990 and thereafter with Crossby Limited since 1995. He has served as a director for over 23 years, with

Page 16

MHE-Public Annexure II Proposed Clause in Article of Association Addition of Definitions under Article 4 of the Articles “Executive Committee” means a committee constituted by the Board to render non -binding advice to the Board and to recommend key business decisions to the Board, including on the following matters: (a) mergers, acquisitions, joint ventures, strategic and financial investments including identification and evaluation of targets and opportunities; (b) the annual budget; (c) development and implementation of overall strategy of the Company and its Group Entities and performance monitoring of the same; and (d) such other matters delegated to it by the Board. “Group Entity(ies)” means individually and collectively: (a) Subsidiaries, and (b) Healthmap Diagnostics Private Limited. “MGHS Group” means Manipal Global Health Services, MEMG International Limited, Dr. Ranjan Ramdas Pai, Cypress Holdings, Manipal Education and Medical Group India Private Limited, MEMG International India Private Limited, and Manipal Research & Management Services International, collectively. “Temasek Group ” means Kangto Investments Pte. Ltd., Kabru Investments Pte. Ltd., and Imperius Healthcare Investments Pte. Ltd, collectively. Insertion of new Article: Article 99.1 Notwithstanding anything contained herein, (i) The Temasek Group shall have the right to nominate up to 3 (three) Directors to the Board and 3 (three) individuals to the Executive Committee until such time that the Temasek Group collectively holds at least 6% (six percent) of the total issued and paid-up equity share capital of the Company on a fully diluted basis; (ii) MGHS Group shall be entitled to nominate up to 2 (two) Directors to the Board and 2 (two) individuals to the Executive Committee until such time that MGHS Group holds at least 6% (six percent) of the total issued and paid-up equity share capital of the Company on a fully diluted basis; (iii) The rights specified in Articles 99.1(i) and 99.1(ii), shall apply mutatis mutandis to the Group Entities.

Page 1

Page 2

Sign in to continue

Page 13

Page 14

Page 15

Page 16

Page 17

Interim report

Page 1

Page 2

Sign in to continue

Page 13

Page 14

Page 15

Page 16

Page 17